Lyra Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Lyra Therapeutics

03/11/2023 12:32

* Lyra Therapeutics Inc  LYRA.OQ   LYRA.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Watertown Massachusetts-based  company is expected to
report
 a 3.5% increase in revenue to $371.6 thousand from $359
thousand a year ago, according to the mean estimate from 5
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Lyra Therapeutics
Inc is
for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $15​, above​ its last closing price of $3.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.40       -0.42      -0.32     Beat    24.4
 Mar. 31 2023  -0.36       -0.36      -0.44     Missed  -20.5
 Dec. 31 2022  -0.39       -0.41      -0.38     Beat    8.2​
 Sep. 30 2022  -0.46       -0.44      -0.40     Beat    9.1
 ​​Jun.        -0.36       -0.37      -0.43     Missed  -15.4
 30 2022                                                
 Mar. 31 2022  -0.93       -0.91      -0.54     Beat    41​
 Dec. 31 2021  -0.79       -0.79      -1.05     Missed  -32.9
 Sep. 30 2021  -0.73       -0.73      -0.85     Missed  -15.6
 This summary was machine generated November 3 at 12:32 GMT.  All
figures in US dollars  unless otherwise stated